Immunitybio is trading 5.2% down now at $6.76 after releasing Q2 earnings that showed a wider GAAP net loss per share, primarily driven by non-cash fair value adjustments on liabilities.
- The company reported a significant 92% year-over-year revenue surge, fueled by strong commercial growth for its ANKTIVA therapy.
- Investors appear to be engaging in profit-taking following a strong multi-month rally, weighing persistent losses against the positive top-line trajectory.